Jade Biosciences Q3 2026 Results: Net Loss of $35.1M, Loss Widens
Jade Biosciences reported a net loss of $131.2 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company strengthened its balance sheet through a June 2026 financing and ATM offerings, ending the period with $475.7 million in cash, cash equivalents, and investments.
- Key figure
- Net loss $35.1M